MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
10.07
+0.70
+7.47%
Pre Market: 9.63 -0.44 -4.37% 08:30 10/05 EDT
OPEN
9.53
PREV CLOSE
9.37
HIGH
10.08
LOW
9.53
VOLUME
4
TURNOVER
--
52 WEEK HIGH
19.32
52 WEEK LOW
5.60
MARKET CAP
782.69M
P/E (TTM)
-3.3872
1D
5D
1M
3M
1Y
5Y
For European pharmas, poor Q3 performance makes the quarter one to forget
Like most of the rest of the stock market, the third quarter is one to forget for major European pharmaceutical companies.In Q3 2022, the S&P 500 was down ~5%. The SPDR MSCI Europe Health Care UCITS ETF, whose ...
Seekingalpha · 3d ago
Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Coherus BioSciences (NASDAQ:CHRS) on Monday said its Ci...
Seekingalpha · 09/19 13:47
BRIEF-Coherus To Launch Cimerli In The United States On Oct. 3
BRIEF-Coherus To Launch Cimerli In The United States On Oct. 3
Reuters · 09/19 11:51
Coherus To Launch CIMERLI In the United States On October 3, 2022
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity -   - Interchangeability
Benzinga · 09/19 11:33
Coherus BioSciences to Make Cimerli Commercially Available in US in October
Coherus BioSciences to Make Cimerli Commercially Available in US in October
MT Newswires · 09/19 10:20
Stada's biosimilar to Roche's eye drug Lucentis gets EMA panel backing for EU approval
A committee of the European Medicines Agency (EMA) recommended the approval of Stada's (<a href="https://seekingalpha.com/symbol/STDAY?utm_...
Seekingalpha · 09/16 13:23
--UBS Adjusts Coherus BioSciences Price Target to $11 From $7, Maintains Neutral Rating
--UBS Adjusts Coherus BioSciences Price Target to $11 From $7, Maintains Neutral Rating
MT Newswires · 09/16 10:30
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14...
GlobeNewswire · 09/12 12:30
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.